0001602078
2017-04-01
2017-09-30
0001602078
2017-09-30
0001602078
2016-03-31
0001602078
2016-04-01
2016-09-30
0001602078
2017-10-31
0001602078
2016-09-30
0001602078
2019-03-31
0001602078
nmrd:PeriodAverageGBPUSDExchangeRateMember
2017-04-01
2017-09-30
0001602078
nmrd:PeriodEndGBPUSDExchangeRateMember
2017-04-01
2017-09-30
0001602078
nmrd:PeriodAverageGBPUSDExchangeRateMember
2016-04-01
2016-09-30
0001602078
nmrd:PeriodEndGBPUSDExchangeRateMember
2016-04-01
2016-09-30
0001602078
2017-12-31
0001602078
2017-01-01
2017-12-31
0001602078
2017-03-31
0001602078
2018-01-01
2018-12-31
0001602078
nmrd:PeriodEndGBPUSDExchangeRateMember
2016-04-01
2017-03-31
0001602078
nmrd:PeriodAverageGBPUSDExchangeRateMember
2016-04-01
2017-03-31
0001602078
nmrd:PeriodEndGBPUSDExchangeRateMember
2017-07-01
2017-09-30
0001602078
nmrd:PeriodAverageGBPUSDExchangeRateMember
2017-07-01
2017-09-30
0001602078
nmrd:PeriodEndGBPUSDExchangeRateMember
2016-07-01
2016-09-30
0001602078
nmrd:PeriodAverageGBPUSDExchangeRateMember
2016-07-01
2016-09-30
0001602078
2017-07-01
2017-09-30
0001602078
2016-07-01
2016-09-30
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
xbrli:pure
10-Q
2017-09-30
false
Nemaura Medical Inc.
0001602078
--03-31
Accelerated Filer
Yes
No
No
2018
Q2
0.001
0.001
420000000
420000000
205000000
205000000
205000000
205000000
0
0
0
0
205000000
4735241
4740000
4358550
1.279
1.340
1.382
1.325
1.245
1.315
1.340
1.283
1.325
1.370
1340000
1245000
597539
9403965
8318282
1350000
911359
1352000
4735000
10000000
10000000
15886
-507376
-494145
-717935
-687609
358285
526795
209087
220714
362064
-389703
159309
140312
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify"><b>NOTE 1 – ORGANIZATION AND PRINCIPAL
ACTIVITIES</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">Nemaura Medical Inc. ("Nemaura"
or the "Company"), through its operating subsidiaries, performs medical device research of a continuous glucose monitoring
system ("CGM"), named sugarBEAT. The sugarBEAT device is a non-invasive, wireless device for use by persons with Type I
and Type II diabetes, and may also be used to screen pre-diabetic patients. The sugarBEAT device extracts analytes, such as glucose,
to the surface of the skin in a non-invasive manner where it is measured using unique sensors and interpreted using a unique algorithm.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">Nemaura is a Nevada holding company organized
in 2013. Nemaura owns one hundred percent (100%) of Region Green Limited, a British Virgin Islands corporation formed ("RGL")
on December 12, 2013.  Region Green Limited owns one hundred percent (100%) of the stock in Dermal Diagnostic (Holdings) Limited,
an England and Wales corporation ("DDHL") formed on December 11, 2013, which in turn owns one hundred percent (100%) of
Dermal Diagnostics Limited, an England and Wales corporation formed on January 20, 2009 ("DDL"), and one hundred percent
(100%) of Trial Clinic Limited, an England and Wales corporation formed on January 12, 2011 ("TCL").</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">DDL is a diagnostic medical device company
headquartered in Loughborough, Leicestershire, England, and is engaged in the discovery, development and commercialization of diagnostic
medical devices. The Company's initial focus has been on the development of the sugarBEAT device, which consists of a disposable
patch containing a sensor, and a non-disposable miniature electronic watch with a re-chargeable power source, which is designed
to enable trending or tracking of blood glucose levels. Except for a US cash account (approximately $48,000 at September 30, 2017),
all of the Company’s operations and assets are located in England.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">The following diagram illustrates our corporate
and shareholder structure as of September 30, 2017:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify"></p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 3pt 0"></p>
<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
<td style="padding-bottom: 2.25pt"><font style="font: 10pt Times New Roman, Times, Serif"> </font></td>
<td colspan="4" style="border: black 2.25pt solid; background-color: #ECE0FC"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Nemaura
Medical Inc.</b></font></p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Nevada
Corporation</b></font></p></td>
<td style="padding-bottom: 2.25pt"><font style="font: 10pt Times New Roman, Times, Serif"> </font></td></tr>
<tr style="vertical-align: top">
<td style="width: 26%"><font style="font: 10pt Times New Roman, Times, Serif"> </font></td>
<td style="width: 22%"><font style="font: 10pt Times New Roman, Times, Serif"> </font></td>
<td style="width: 4%"><font style="font: 10pt Times New Roman, Times, Serif"> </font></td>
<td style="width: 4%; border-left: black 2.25pt solid"><font style="font: 10pt Times New Roman, Times, Serif"> </font></td>
<td style="width: 22%"><font style="font: 10pt Times New Roman, Times, Serif"> </font></td>
<td style="width: 22%"><font style="font: 10pt Times New Roman, Times, Serif"> </font></td></tr>
<tr style="vertical-align: top">
<td style="padding-bottom: 2.25pt"><font style="font: 10pt Times New Roman, Times, Serif"> </font></td>
<td colspan="4" style="border: black 2.25pt solid; background-color: #ECE0FC"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Region
Green Limited</b></font></p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>British
Virgin Islands Corporation</b></font></p></td>
<td style="padding-bottom: 2.25pt"><font style="font: 10pt Times New Roman, Times, Serif"> </font></td></tr>
<tr style="vertical-align: top">
<td><font style="font: 10pt Times New Roman, Times, Serif"> </font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif"> </font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif"> </font></td>
<td style="border-left: black 2.25pt solid"><font style="font: 10pt Times New Roman, Times, Serif"> </font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif"> </font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif"> </font></td></tr>
<tr style="vertical-align: top">
<td style="padding-bottom: 2.25pt"><font style="font: 10pt Times New Roman, Times, Serif"> </font></td>
<td colspan="4" style="border: black 2.25pt solid; background-color: #ECE0FC"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Dermal
Diagnostics (Holdings) Limited</b></font></p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>England
and Wales Corporation</b></font></p></td>
<td style="padding-bottom: 2.25pt"><font style="font: 10pt Times New Roman, Times, Serif"> </font></td></tr>
<tr style="vertical-align: top">
<td><font style="font: 10pt Times New Roman, Times, Serif"> </font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif"> </font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif"> </font></td>
<td style="border-left: black 2.25pt solid"><font style="font: 10pt Times New Roman, Times, Serif"> </font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif"> </font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif"> </font></td></tr>
<tr style="vertical-align: top">
<td><font style="font: 10pt Times New Roman, Times, Serif"> </font></td>
<td style="border-top: black 2.25pt solid; border-left: black 2.25pt solid"><font style="font: 10pt Times New Roman, Times, Serif"> </font></td>
<td style="border-top: black 2.25pt solid"><font style="font: 10pt Times New Roman, Times, Serif"> </font></td>
<td style="border-top: black 2.25pt solid"><font style="font: 10pt Times New Roman, Times, Serif"> </font></td>
<td style="border-top: black 2.25pt solid; border-right: black 2.25pt solid"><font style="font: 10pt Times New Roman, Times, Serif"> </font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif"> </font></td></tr>
<tr style="vertical-align: top">
<td colspan="2" style="border: black 2.25pt solid; background-color: #ECE0FC"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Dermal
Diagnostics Limited</b></font></p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>England
and Wales Corporation</b></font></p></td>
<td style="padding-bottom: 2.25pt"><font style="font: 10pt Times New Roman, Times, Serif"> </font></td>
<td style="padding-bottom: 2.25pt"><font style="font: 10pt Times New Roman, Times, Serif"> </font></td>
<td colspan="2" style="border: black 2.25pt solid; background-color: #ECE0FC"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Trial
Clinic Limited</b></font></p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>England
and Wales Corporation</b></font></p></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify"></p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">The Company has a limited operating history,
recurring losses from operations and an accumulated deficit of $7,953,451 as of September 30, 2017.  The Company expects to
continue to incur losses from operations at least until clinical trials are completed later this calendar year and the product
becomes available to be marketed.  Management has evaluated its ability to continue as a going concern for the next twelve
months from the issuance of these September 30, 2017 consolidated financial statements, and considered the expected expenses to
be incurred along with its available cash, and has determined that there is not substantial doubt as to its ability to continue
as a going concern for at least one year subsequent to the date of issuance of these financial statements. The Company has $597,539
of readily available cash on hand at September 30, 2017 and approximately $1.35 million will be available in December 2017, which
is currently in a fixed rate deposit account.  In addition, the Company has approximately $4.74 million of cash in a fixed
rate deposit account which matures in December 2018.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">Management's strategic plans include the
following:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">- continuing to advance commercialization
of the Company's principal product, in the UK, European and other international markets;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">- pursuing additional capital raising opportunities;
and</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">- continuing to explore and execute prospective
partnering or distribution opportunities.</p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify"></p>
67000
440266
-40164
46420
19889
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">These amounts are unsecured, interest free,
and payable on demand.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify"> </p>
<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
<td style="padding-bottom: 1.5pt"> </td>
<td style="padding-bottom: 1.5pt"> </td>
<td colspan="2" style="border-bottom: black 1.5pt solid; padding-bottom: 1.5pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Six Months Ended</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>September 30, 2017</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(unaudited)</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>($)</b></p></td>
<td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td>
<td style="padding-bottom: 1.5pt"> </td>
<td colspan="2" style="border-bottom: black 1.5pt solid">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Six Months Ended</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>September 30, 2016</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(unaudited)</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>($)</b></p></td>
<td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="width: 68%"><font style="font-size: 10pt">Balance due from (to) Pharma and NDM at beginning of period</font></td>
<td style="width: 1%"> </td>
<td style="width: 1%"> </td>
<td style="width: 13%; text-align: right"><font style="font-size: 10pt">(687,609</font></td>
<td nowrap="nowrap" style="width: 1%"><font style="font-size: 10pt">)</font></td>
<td style="width: 1%"> </td>
<td style="width: 1%"> </td>
<td style="width: 13%; text-align: right"><font style="font-size: 10pt">(494,145</font></td>
<td nowrap="nowrap" style="width: 1%"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td><font style="font-size: 10pt">Amounts invoiced by Pharma to DDL and TCL (1)</font></td>
<td> </td>
<td> </td>
<td style="text-align: right"><font style="font-size: 10pt">(239,758</font></td>
<td nowrap="nowrap"><font style="font-size: 10pt">)</font></td>
<td> </td>
<td> </td>
<td style="text-align: right"><font style="font-size: 10pt">(286,096</font></td>
<td nowrap="nowrap"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td><font style="font-size: 10pt">Amounts invoiced by DDL to Pharma</font></td>
<td> </td>
<td> </td>
<td style="text-align: right"><font style="font-size: 10pt">-</font></td>
<td nowrap="nowrap"> </td>
<td> </td>
<td> </td>
<td style="text-align: right"><font style="font-size: 10pt">15,886</font></td>
<td nowrap="nowrap"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td><font style="font-size: 10pt">Amounts repaid by DDL to Pharma</font></td>
<td> </td>
<td> </td>
<td style="text-align: right"><font style="font-size: 10pt">440,266</font></td>
<td nowrap="nowrap"> </td>
<td> </td>
<td> </td>
<td style="text-align: right"><font style="font-size: 10pt">-</font></td>
<td nowrap="nowrap"> </td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td><font style="font-size: 10pt">Amounts paid by DDL on behalf of Pharma</font></td>
<td> </td>
<td> </td>
<td style="text-align: right"><font style="font-size: 10pt">19,889</font></td>
<td nowrap="nowrap"> </td>
<td> </td>
<td> </td>
<td style="text-align: right"><font style="font-size: 10pt">-</font></td>
<td nowrap="nowrap"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Foreign exchange differences</font></td>
<td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: black 1.5pt solid; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: black 1.5pt solid; padding-bottom: 1.5pt; text-align: right"><font style="font-size: 10pt">(40,164</font></td>
<td nowrap="nowrap" style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
<td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: black 1.5pt solid"> </td>
<td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">46,420</font></td>
<td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="padding-bottom: 3pt"><font style="font-size: 10pt">Balance due to Pharma and NDM at end of the period</font></td>
<td style="padding-bottom: 3pt"> </td>
<td style="border-bottom: black 2.25pt double; padding-bottom: 3pt"> </td>
<td style="border-bottom: black 2.25pt double; padding-bottom: 3pt; text-align: right"><font style="font-size: 10pt">(507,376</font></td>
<td nowrap="nowrap" style="padding-bottom: 3pt"><font style="font-size: 10pt">)</font></td>
<td style="padding-bottom: 3pt"> </td>
<td style="border-bottom: black 2.25pt double"> </td>
<td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(717,935</font></td>
<td nowrap="nowrap" style="padding-bottom: 3pt"><font style="font-size: 10pt">)</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">The translation rates are as follows:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0"> </p>
<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
<td style="padding-bottom: 1.5pt"> </td>
<td style="padding-bottom: 1.5pt"> </td>
<td colspan="2" style="border-bottom: black 1.5pt solid; padding-bottom: 1.5pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Six months ended</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b> September 30,</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2017</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(unaudited)</b></p></td>
<td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td>
<td style="padding-bottom: 1.5pt"> </td>
<td colspan="2" style="border-bottom: black 1.5pt solid; padding-bottom: 1.5pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Six months ended </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>September 30,</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2016</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(unaudited)</b></p></td>
<td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td>
<td style="padding-bottom: 1.5pt"> </td>
<td colspan="2" style="border-bottom: black 1.5pt solid; padding-bottom: 1.5pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Three months ended</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>September 30,</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2017</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(unaudited)</b></p></td>
<td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td>
<td style="padding-bottom: 1.5pt"> </td>
<td colspan="2" style="border-bottom: black 1.5pt solid; padding-bottom: 1.5pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Three months ended </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>September 30,</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2016</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(unaudited)</b></p></td>
<td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td>
<td style="padding-bottom: 1.5pt"> </td>
<td colspan="2" style="border-bottom: black 1.5pt solid">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Twelve months ended</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>March 31,</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2017</b></p></td>
<td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top; width: 20%"><font style="font-size: 10pt">Period end GBP : US$ exchange rate</font></td>
<td style="vertical-align: bottom; width: 1%"> </td>
<td style="vertical-align: bottom; width: 1%"> </td>
<td style="vertical-align: bottom; width: 13%; text-align: right"><font style="font-size: 10pt">1.340</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td>
<td style="vertical-align: bottom; width: 1%"> </td>
<td style="vertical-align: bottom; width: 1%"> </td>
<td style="vertical-align: bottom; width: 13%; text-align: right"><font style="font-size: 10pt">1.325</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td>
<td style="vertical-align: bottom; width: 1%"> </td>
<td style="vertical-align: bottom; width: 1%"> </td>
<td style="vertical-align: bottom; width: 13%; text-align: right"><font style="font-size: 10pt">1.340</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td>
<td style="vertical-align: bottom; width: 1%"> </td>
<td style="vertical-align: bottom; width: 1%"> </td>
<td style="vertical-align: bottom; width: 13%; text-align: right"><font style="font-size: 10pt">1.325</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td>
<td style="vertical-align: bottom; width: 1%"> </td>
<td style="vertical-align: bottom; width: 1%"> </td>
<td style="vertical-align: bottom; width: 13%; text-align: right"><font style="font-size: 10pt">1.245</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td></tr>
<tr style="background-color: white">
<td style="vertical-align: top"><font style="font-size: 10pt">Average period/yearly GBP : US$ exchange rate</font></td>
<td style="vertical-align: bottom"> </td>
<td style="vertical-align: bottom"> </td>
<td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">1.279</font></td>
<td nowrap="nowrap" style="vertical-align: bottom"> </td>
<td style="vertical-align: bottom"> </td>
<td style="vertical-align: bottom"> </td>
<td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">1.382</font></td>
<td nowrap="nowrap" style="vertical-align: bottom"> </td>
<td style="vertical-align: bottom"> </td>
<td style="vertical-align: bottom"> </td>
<td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">1.283</font></td>
<td nowrap="nowrap" style="vertical-align: bottom"> </td>
<td style="vertical-align: bottom"> </td>
<td style="vertical-align: bottom"> </td>
<td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">1.370</font></td>
<td nowrap="nowrap" style="vertical-align: bottom"> </td>
<td style="vertical-align: bottom"> </td>
<td style="vertical-align: bottom"> </td>
<td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">1.315</font></td>
<td nowrap="nowrap" style="vertical-align: bottom"> </td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">(m) Risks and uncertainties</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">The Company is in the development stage
of one primary product that it expects to introduce to the UK market after completion of clinical trials and CE mark approval (European
Union approval of the product). The Company has entered into sales and marketing agreements for the product, but has not yet entered
into manufacturing agreements.  These matters raise uncertainties as regulatory acceptance of the Company’s primary
product development efforts and if acceptance is attained, the cost structure to produce the product.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">(l) Recent accounting pronouncements</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">The Company continually assesses any new
accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the
Company's financial reporting, the Company undertakes a study to determine the consequences of the change to its consolidated financial
statements and assures that there are proper controls in place to ascertain that the Company's consolidated financial statements
properly reflect the change.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">In May 2014, the Financial Accounting Standards
Board ("FASB") issued Accounting Standards Updates ("ASU") No. 2014-09, Revenue from Contracts with Customers.
ASU 2014-09 has been modified multiple times since its initial release. This ASU outlines a single comprehensive model for entities
to use in accounting for revenue arising from contracts with customers and will replace most existing revenue recognition guidance
in U.S. GAAP when it becomes effective. ASU 2014-09, as amended, becomes effective for annual reporting periods beginning after
December 15, 2017. Early adoption is permitted. The Company is currently evaluating the impact that this standard will have on
its financial statements and related disclosures. The impact is expected to be insignificant until the Company begins to generate
revenue, except as to the possible impact related to the deferred revenue recorded in connection with the licensing agreement
described in Note 4 which the Company is currently evaluating. The standard permits the use of either the retrospective or cumulative
effect transition method. The Company has not yet selected a transition method.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">In March 2016, the FASB issued ASU No.
2016-02, Leases. The main difference between the provisions of ASU No. 2016-02 and previous U.S. GAAP is the recognition of right-of-use
assets and lease liabilities by lessees for those leases classified as operating leases under previous U.S. GAAP. ASU No. 2016-
02 retains a distinction between finance leases and operating leases, and the recognition, measurement, and presentation of expenses
and cash flows arising from a lease by a lessee have not significantly changed from previous U.S. GAAP. For leases with a term
of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize
right-of-use assets and lease liabilities. The accounting applied by a lessor is largely unchanged from that applied under previous
U.S. GAAP. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period
presented using a modified retrospective approach. This ASU is effective for public business entities in fiscal years, and interim
periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted as of the beginning of any interim
or annual reporting period. The Company has not yet determined the effect of the standard on its ongoing reporting.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">In August 2016, the FASB issued ASU No.
2016-15, Statement of Cash Flows - Classification of Certain Cash Receipts and Cash Payments. ASU No. 2016-15 is intended to reduce
diversity in how certain cash receipts and cash payments are presented in the statement of cash flows. The new guidance clarifies
the classification of cash activity related to debt prepayment or debt extinguishment costs, settlement of zero-coupon debt instruments,
contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, proceeds
from the settlement of corporate and bank-owned life insurance policies, distributions received from equity-method investments,
and beneficial interests in securitization transactions. The guidance also describes a predominance principle pursuant to which
cash flows with aspects of more than one class that cannot be separated should be classified based on the activity that is likely
to be the predominant source or use of cash flow. This ASU is effective for public entities for annual and interim periods beginning
after December 15, 2017. Early adoption is permitted as of the beginning of any interim or annual reporting period. The Company
is currently evaluating the impact this standard will have on its financial statements and related disclosures, but does not expect
it to have a material effect on the Company's consolidated financial statements and related disclosures.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">In November 2016, the FASB issued ASU No.
2016-18, Statement of Cash Flows - Restricted Cash. ASU 2016-18 requires entities to show the changes in the total of cash, cash
equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. When cash, cash equivalents, restricted
cash and restricted cash equivalents are presented in more than one line item on the balance sheet, a reconciliation of the totals
in the statement of cash flows to the related captions in the balance sheet is required. This ASU is effective for public entities
for annual and interim periods beginning after December 15, 2017. Early adoption is permitted as of the beginning of any interim
or annual reporting period. The Company is currently evaluating the impact this standard will have on its financial statements
and related disclosures.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">(k) Foreign currency translation</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">The functional currency of the Company
is the Great Britain Pound Sterling ("GBP").  The reporting currency is the United States dollar (US$).  Stockholders'
equity is translated into United States dollars from GBP at historical exchange rates.  Assets and liabilities are translated
at the exchange rates as of balance sheet date. Income and expenditures are translated at the average exchange rates prevailing
during the reporting period.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">The translation rates are as follows:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0"> </p>
<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
<td style="padding-bottom: 1.5pt"> </td>
<td style="padding-bottom: 1.5pt"> </td>
<td colspan="2" style="border-bottom: black 1.5pt solid; padding-bottom: 1.5pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Six months ended</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b> September 30,</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2017</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(unaudited)</b></p></td>
<td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td>
<td style="padding-bottom: 1.5pt"> </td>
<td colspan="2" style="border-bottom: black 1.5pt solid; padding-bottom: 1.5pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Six months ended </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>September 30,</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2016</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(unaudited)</b></p></td>
<td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td>
<td style="padding-bottom: 1.5pt"> </td>
<td colspan="2" style="border-bottom: black 1.5pt solid; padding-bottom: 1.5pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Three months ended</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>September 30,</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2017</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(unaudited)</b></p></td>
<td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td>
<td style="padding-bottom: 1.5pt"> </td>
<td colspan="2" style="border-bottom: black 1.5pt solid; padding-bottom: 1.5pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Three months ended </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>September 30,</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2016</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(unaudited)</b></p></td>
<td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td>
<td style="padding-bottom: 1.5pt"> </td>
<td colspan="2" style="border-bottom: black 1.5pt solid">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Twelve months ended</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>March 31,</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2017</b></p></td>
<td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top; width: 20%"><font style="font-size: 10pt">Period end GBP : US$ exchange rate</font></td>
<td style="vertical-align: bottom; width: 1%"> </td>
<td style="vertical-align: bottom; width: 1%"> </td>
<td style="vertical-align: bottom; width: 13%; text-align: right"><font style="font-size: 10pt">1.340</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td>
<td style="vertical-align: bottom; width: 1%"> </td>
<td style="vertical-align: bottom; width: 1%"> </td>
<td style="vertical-align: bottom; width: 13%; text-align: right"><font style="font-size: 10pt">1.325</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td>
<td style="vertical-align: bottom; width: 1%"> </td>
<td style="vertical-align: bottom; width: 1%"> </td>
<td style="vertical-align: bottom; width: 13%; text-align: right"><font style="font-size: 10pt">1.340</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td>
<td style="vertical-align: bottom; width: 1%"> </td>
<td style="vertical-align: bottom; width: 1%"> </td>
<td style="vertical-align: bottom; width: 13%; text-align: right"><font style="font-size: 10pt">1.325</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td>
<td style="vertical-align: bottom; width: 1%"> </td>
<td style="vertical-align: bottom; width: 1%"> </td>
<td style="vertical-align: bottom; width: 13%; text-align: right"><font style="font-size: 10pt">1.245</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td></tr>
<tr style="background-color: white">
<td style="vertical-align: top"><font style="font-size: 10pt">Average period/yearly GBP : US$ exchange rate</font></td>
<td style="vertical-align: bottom"> </td>
<td style="vertical-align: bottom"> </td>
<td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">1.279</font></td>
<td nowrap="nowrap" style="vertical-align: bottom"> </td>
<td style="vertical-align: bottom"> </td>
<td style="vertical-align: bottom"> </td>
<td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">1.382</font></td>
<td nowrap="nowrap" style="vertical-align: bottom"> </td>
<td style="vertical-align: bottom"> </td>
<td style="vertical-align: bottom"> </td>
<td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">1.283</font></td>
<td nowrap="nowrap" style="vertical-align: bottom"> </td>
<td style="vertical-align: bottom"> </td>
<td style="vertical-align: bottom"> </td>
<td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">1.370</font></td>
<td nowrap="nowrap" style="vertical-align: bottom"> </td>
<td style="vertical-align: bottom"> </td>
<td style="vertical-align: bottom"> </td>
<td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">1.315</font></td>
<td nowrap="nowrap" style="vertical-align: bottom"> </td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">Adjustments resulting from translating
the financial statements into the United States dollar are recorded as a separate component of accumulated other comprehensive
loss in stockholders' equity.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify"> (j) Use of estimates</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">The preparation of financial statements
in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the
financial statements and the reported amounts of revenues and expenses during the year. Actual results may differ from those estimates.</p>
<table cellspacing="0" cellpadding="0" style="width: 100%">
<tr style="vertical-align: top">
<td style="width: 4%; font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt">(i)</font></td>
<td style="width: 96%; font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt">Earnings per share</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">Basic earnings per share is computed by
dividing income available to common stockholders by the weighted-average number of common shares outstanding during the period.
There were no potentially dilutive securities as of September 30, 2017 and 2016. For the three month and six month periods ended
September 30, 2017 and 2016, warrants to purchase 10 million shares of common stock were anti-dilutive and were excluded from the
calculation of diluted loss per share.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">(h) Income taxes</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">Income taxes are accounted for under the
asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax consequences attributable
to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases,
and operating loss carry forwards. Deferred income tax assets and liabilities are measured using enacted tax rates expected to
apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect
on deferred income tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the
enactment date. A valuation allowance is provided to reduce the carrying amount of deferred income tax assets if it is considered
more likely than not that some portion, or all, of the deferred income tax assets will not be realized.<br />
 </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">The Company recognizes the effect of income
tax positions only if those positions are more likely than not of being sustained.  Recognized income tax positions are measured
at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in
the period in which the change in judgment occurs. The Company has elected to classify interest and penalties related to unrecognized
tax benefits as part of income tax expense in the consolidated statements of comprehensive loss. The Company does not have any
accrued interest or penalties associated with any unrecognized tax benefits, nor was any interest expense related to unrecognized
tax benefits recognized for the three months ended September 30, 2017 and 2016.  The Company’s deferred tax asset consists
primarily of net operating loss carried forwards, and are fully allowed for as realization of these assets is not considered to
be more likely than not.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">(g) Research and development expenses</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">The Company charges research and development
expenses to operations as incurred. Research and development expenses primarily consist of salaries and related expenses for personnel
and outside contractor and consulting services. Other research and development expenses include the costs of materials and supplies
used in research and development, prototype manufacturing, clinical studies, related information technology and an allocation of
facilities costs.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">(f) Revenue recognition</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">Revenue is recognized when the four basic
criteria of revenue recognition are met:  (1) a contractual agreement exists; (2) transfer of rights has been completed; (3)
the fee is fixed or determinable; and (4) collectability is reasonably assured.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">The Company may enter into product development
and other agreements and with collaborative partners. The terms of the agreements may include nonrefundable signing and licensing
fees, milestone payments and royalties on any product sales derived from collaborations.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">The Company recognizes up front license
payments as revenue upon delivery of the license only if the license has stand alone value to the customer. However, where further
performance criteria must be met, revenue is deferred and recognized on a straight line basis over the period the Company is expected
to complete its performance obligations.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">Royalty revenue will be recognized upon
the sale of the related products provided the Company has no remaining performance obligations under the agreement.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">(e) Intangible assets</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">Intangible assets consist of licenses and
patents associated with the sugarBEAT device and are amortized on a straight-line basis, generally over their legal lives of up
to 20 years.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">(d) Property and equipment</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">Property and equipment is stated at cost
and depreciated using the straight-line method over the estimated useful lives of the assets, generally four years for fixtures
and fittings.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">(c) Fair value of financial instruments</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">The Company's financial instruments primarily
consist of cash, fixed rate cash accounts, and accounts payable.  As of the balance sheet dates, the estimated fair values
of non-related party financial instruments were not materially different from their carrying values as presented, due to their
short maturities. The fair value of amounts payable to related parties are not practicable to estimate due to the related party
nature of the underlying transactions.</p>
<table cellspacing="0" cellpadding="0" style="width: 100%">
<tr style="vertical-align: top">
<td style="width: 4%; font: 12pt Times New Roman, Times, Serif"><font style="font-size: 10pt">(b)</font></td>
<td style="width: 96%; font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt">Fixed rate cash accounts:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">From time to time the Company invests funds
in fixed rate cash savings accounts.  These accounts, at the time of the initial investment, provide a higher interest rate
than other bank accounts, and also require the Company to maintain the funds in the accounts for a period of time, $1,352,000 through
December 2017 and $4,735,000 through December 2018.  Early withdrawal may generally be made for liquidity needs.</p>
<table cellspacing="0" cellpadding="0" style="width: 100%">
<tr style="vertical-align: top">
<td style="width: 4%; font: 12pt Times New Roman, Times, Serif"><font style="font-size: 10pt">(a)</font></td>
<td style="width: 96%; font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt">Cash</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">Cash includes cash equivalents, which the
Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. 
Cash and cash equivalents consist primarily of cash deposits maintained in the United Kingdom. From time to time, the Company's
cash account balances exceed amounts covered by the Financial Services Compensation Scheme. The Company has never suffered a loss
due to such excess balances.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify"><b>NOTE 5 – RELATED PARTY TRANSACTIONS</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">Nemaura Pharma Limited (Pharma) and NDM
Technologies Limited (NDM) are entities controlled by the Company’s majority shareholder, Dewan F.H. Chowdhury.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">In accordance with the United States Securities
and Exchange Commission (SEC) Staff Accounting Bulletin 55, these financial statements are intended to reflect all costs associated
with the operations of DDL and TCL.  Pharma has invoiced DDL and TCL for research and development services. In addition, certain
operating expenses of DDL and TCL were incurred and paid by Pharma and NDM which have been invoiced to the Company.  Certain
costs incurred by Pharma and NDM are directly attributable to DDL and TCL and such costs were billed to the Company.  Prior
to the year ended March 31, 2016, other costs were shared between the organizations.  In situations where the costs were shared,
expense has been allocated between Pharma and NDM and DDL and TCL using a fixed percentage allocation and were billed to the Company. 
Management believes the allocation methodologies used are reasonable.  DDL and TCL advanced Pharma certain amounts to cover
a portion of the costs.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">Following is a summary of activity between
the Company and Pharma and NDM for the six months ended September 30, 2017 and 2016. These amounts are unsecured, interest free,
and payable on demand.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify"> </p>
<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
<td style="padding-bottom: 1.5pt"> </td>
<td style="padding-bottom: 1.5pt"> </td>
<td colspan="2" style="border-bottom: black 1.5pt solid; padding-bottom: 1.5pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Six Months Ended</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>September 30, 2017</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(unaudited)</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>($)</b></p></td>
<td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td>
<td style="padding-bottom: 1.5pt"> </td>
<td colspan="2" style="border-bottom: black 1.5pt solid">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Six Months Ended</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>September 30, 2016</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(unaudited)</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>($)</b></p></td>
<td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="width: 68%"><font style="font-size: 10pt">Balance due from (to) Pharma and NDM at beginning of period</font></td>
<td style="width: 1%"> </td>
<td style="width: 1%"> </td>
<td style="width: 13%; text-align: right"><font style="font-size: 10pt">(687,609</font></td>
<td nowrap="nowrap" style="width: 1%"><font style="font-size: 10pt">)</font></td>
<td style="width: 1%"> </td>
<td style="width: 1%"> </td>
<td style="width: 13%; text-align: right"><font style="font-size: 10pt">(494,145</font></td>
<td nowrap="nowrap" style="width: 1%"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td><font style="font-size: 10pt">Amounts invoiced by Pharma to DDL and TCL (1)</font></td>
<td> </td>
<td> </td>
<td style="text-align: right"><font style="font-size: 10pt">(239,758</font></td>
<td nowrap="nowrap"><font style="font-size: 10pt">)</font></td>
<td> </td>
<td> </td>
<td style="text-align: right"><font style="font-size: 10pt">(286,096</font></td>
<td nowrap="nowrap"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td><font style="font-size: 10pt">Amounts invoiced by DDL to Pharma</font></td>
<td> </td>
<td> </td>
<td style="text-align: right"><font style="font-size: 10pt">-</font></td>
<td nowrap="nowrap"> </td>
<td> </td>
<td> </td>
<td style="text-align: right"><font style="font-size: 10pt">15,886</font></td>
<td nowrap="nowrap"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td><font style="font-size: 10pt">Amounts repaid by DDL to Pharma</font></td>
<td> </td>
<td> </td>
<td style="text-align: right"><font style="font-size: 10pt">440,266</font></td>
<td nowrap="nowrap"> </td>
<td> </td>
<td> </td>
<td style="text-align: right"><font style="font-size: 10pt">-</font></td>
<td nowrap="nowrap"> </td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td><font style="font-size: 10pt">Amounts paid by DDL on behalf of Pharma</font></td>
<td> </td>
<td> </td>
<td style="text-align: right"><font style="font-size: 10pt">19,889</font></td>
<td nowrap="nowrap"> </td>
<td> </td>
<td> </td>
<td style="text-align: right"><font style="font-size: 10pt">-</font></td>
<td nowrap="nowrap"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Foreign exchange differences</font></td>
<td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: black 1.5pt solid; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: black 1.5pt solid; padding-bottom: 1.5pt; text-align: right"><font style="font-size: 10pt">(40,164</font></td>
<td nowrap="nowrap" style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
<td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: black 1.5pt solid"> </td>
<td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">46,420</font></td>
<td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="padding-bottom: 3pt"><font style="font-size: 10pt">Balance due to Pharma and NDM at end of the period</font></td>
<td style="padding-bottom: 3pt"> </td>
<td style="border-bottom: black 2.25pt double; padding-bottom: 3pt"> </td>
<td style="border-bottom: black 2.25pt double; padding-bottom: 3pt; text-align: right"><font style="font-size: 10pt">(507,376</font></td>
<td nowrap="nowrap" style="padding-bottom: 3pt"><font style="font-size: 10pt">)</font></td>
<td style="padding-bottom: 3pt"> </td>
<td style="border-bottom: black 2.25pt double"> </td>
<td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(717,935</font></td>
<td nowrap="nowrap" style="padding-bottom: 3pt"><font style="font-size: 10pt">)</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0">(1)  These amounts are included primarily in research and
development expenses charged to the Company by Pharma and NDM.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify"><b>NOTE 4 – LICENSING AGREEMENT</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">In March 2014, the Company entered into an Exclusive Marketing
Rights Agreement with an unrelated third party, that granted to the third party the exclusive right to market and promote the sugarBEAT
device and related patches under its own brand in the United Kingdom and the Republic of Ireland, the Channel Islands and the Isle
of Man. The Company received a non-refundable, up front cash payment of GBP 1,000,000 (approximately $1.340 million and $1.245
million as of September 30, 2017 and March 31, 2017 respectively) which is wholly non-refundable, upon signing the agreement.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">As the Company has continuing performance obligations under
the agreement, the up front fees received from this agreement have been deferred and will be recorded as income over the term of
the commercial licensing agreement beginning from the date of clinical evaluation approval. As the Company expects commercialization
of the sugarBEAT device to occur in the year ending March 31, 2019, approximately $67,000 of the deferred revenue has been classified
as a current liability.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">In April 2014, a Letter of Intent was signed
with the third party which specified a 10 year term and in November 2015, a Licence, Supply and Distribution agreement with an
initial 5 year term was executed. The Company grants the exclusive right to market and promote its product in the United Kingdom,
and purchase the product at specified prices.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify"><b>NOTE 3 – SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0"> </p>
<table cellspacing="0" cellpadding="0" style="width: 100%">
<tr style="vertical-align: top">
<td style="width: 4%; font: 12pt Times New Roman, Times, Serif"><font style="font-size: 10pt">(a)</font></td>
<td style="width: 96%; font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt">Cash</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">Cash includes cash equivalents, which the
Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. 
Cash and cash equivalents consist primarily of cash deposits maintained in the United Kingdom. From time to time, the Company's
cash account balances exceed amounts covered by the Financial Services Compensation Scheme. The Company has never suffered a loss
due to such excess balances.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0"> </p>
<table cellspacing="0" cellpadding="0" style="width: 100%">
<tr style="vertical-align: top">
<td style="width: 4%; font: 12pt Times New Roman, Times, Serif"><font style="font-size: 10pt">(b)</font></td>
<td style="width: 96%; font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt">Fixed rate cash accounts:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">From time to time the Company invests funds
in fixed rate cash savings accounts.  These accounts, at the time of the initial investment, provide a higher interest rate
than other bank accounts, and also require the Company to maintain the funds in the accounts for a period of time, $1,352,000 through
December 2017 and $4,735,000 through December 2018.  Early withdrawal may generally be made for liquidity needs.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">(c) Fair value of financial instruments</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">The Company's financial instruments primarily
consist of cash, fixed rate cash accounts, and accounts payable.  As of the balance sheet dates, the estimated fair values
of non-related party financial instruments were not materially different from their carrying values as presented, due to their
short maturities. The fair value of amounts payable to related parties are not practicable to estimate due to the related party
nature of the underlying transactions.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">(d) Property and equipment</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">Property and equipment is stated at cost
and depreciated using the straight-line method over the estimated useful lives of the assets, generally four years for fixtures
and fittings.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">(e) Intangible assets</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">Intangible assets consist of licenses and
patents associated with the sugarBEAT device and are amortized on a straight-line basis, generally over their legal lives of up
to 20 years.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">(f) Revenue recognition</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">Revenue is recognized when the four basic
criteria of revenue recognition are met:  (1) a contractual agreement exists; (2) transfer of rights has been completed; (3)
the fee is fixed or determinable; and (4) collectability is reasonably assured.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">The Company may enter into product development
and other agreements and with collaborative partners. The terms of the agreements may include nonrefundable signing and licensing
fees, milestone payments and royalties on any product sales derived from collaborations.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">The Company recognizes up front license
payments as revenue upon delivery of the license only if the license has stand alone value to the customer. However, where further
performance criteria must be met, revenue is deferred and recognized on a straight line basis over the period the Company is expected
to complete its performance obligations.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">Royalty revenue will be recognized upon
the sale of the related products provided the Company has no remaining performance obligations under the agreement.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">(g) Research and development expenses</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">The Company charges research and development
expenses to operations as incurred. Research and development expenses primarily consist of salaries and related expenses for personnel
and outside contractor and consulting services. Other research and development expenses include the costs of materials and supplies
used in research and development, prototype manufacturing, clinical studies, related information technology and an allocation of
facilities costs.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">(h) Income taxes</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">Income taxes are accounted for under the
asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax consequences attributable
to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases,
and operating loss carry forwards. Deferred income tax assets and liabilities are measured using enacted tax rates expected to
apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect
on deferred income tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the
enactment date. A valuation allowance is provided to reduce the carrying amount of deferred income tax assets if it is considered
more likely than not that some portion, or all, of the deferred income tax assets will not be realized.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0"><br />
 The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. 
Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes
in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company has elected to classify
interest and penalties related to unrecognized tax benefits as part of income tax expense in the consolidated statements of comprehensive
loss. The Company does not have any accrued interest or penalties associated with any unrecognized tax benefits, nor was any interest
expense related to unrecognized tax benefits recognized for the three months ended September 30, 2017 and 2016.  The Company’s
deferred tax asset consists primarily of net operating loss carried forwards, and are fully allowed for as realization of these
assets is not considered to be more likely than not.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0"> </p>
<table cellspacing="0" cellpadding="0" style="width: 100%">
<tr style="vertical-align: top">
<td style="width: 4%; font: 12pt Times New Roman, Times, Serif"><font style="font-size: 10pt">(i)</font></td>
<td style="width: 96%; font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt">Earnings per share</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">Basic earnings per share is computed by
dividing income available to common stockholders by the weighted-average number of common shares outstanding during the period.
There were no potentially dilutive securities as of September 30, 2017 and 2016. For the three month and six month periods ended
September 30, 2017 and 2016, warrants to purchase 10 million shares of common stock were anti-dilutive and were excluded from the
calculation of diluted loss per share.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify"> (j) Use of estimates</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">The preparation of financial statements
in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the
financial statements and the reported amounts of revenues and expenses during the year. Actual results may differ from those estimates.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">(k) Foreign currency translation</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">The functional currency of the Company
is the Great Britain Pound Sterling ("GBP").  The reporting currency is the United States dollar (US$).  Stockholders'
equity is translated into United States dollars from GBP at historical exchange rates.  Assets and liabilities are translated
at the exchange rates as of balance sheet date. Income and expenditures are translated at the average exchange rates prevailing
during the reporting period.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">The translation rates are as follows:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0"> </p>
<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
<td style="padding-bottom: 1.5pt"> </td>
<td style="padding-bottom: 1.5pt"> </td>
<td colspan="2" style="border-bottom: black 1.5pt solid; padding-bottom: 1.5pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Six months ended</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b> September 30,</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2017</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(unaudited)</b></p></td>
<td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td>
<td style="padding-bottom: 1.5pt"> </td>
<td colspan="2" style="border-bottom: black 1.5pt solid; padding-bottom: 1.5pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Six months ended </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>September 30,</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2016</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(unaudited)</b></p></td>
<td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td>
<td style="padding-bottom: 1.5pt"> </td>
<td colspan="2" style="border-bottom: black 1.5pt solid; padding-bottom: 1.5pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Three months ended</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>September 30,</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2017</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(unaudited)</b></p></td>
<td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td>
<td style="padding-bottom: 1.5pt"> </td>
<td colspan="2" style="border-bottom: black 1.5pt solid; padding-bottom: 1.5pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Three months ended </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>September 30,</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2016</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(unaudited)</b></p></td>
<td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td>
<td style="padding-bottom: 1.5pt"> </td>
<td colspan="2" style="border-bottom: black 1.5pt solid">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Twelve months ended</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>March 31,</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2017</b></p></td>
<td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top; width: 20%"><font style="font-size: 10pt">Period end GBP : US$ exchange rate</font></td>
<td style="vertical-align: bottom; width: 1%"> </td>
<td style="vertical-align: bottom; width: 1%"> </td>
<td style="vertical-align: bottom; width: 13%; text-align: right"><font style="font-size: 10pt">1.340</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td>
<td style="vertical-align: bottom; width: 1%"> </td>
<td style="vertical-align: bottom; width: 1%"> </td>
<td style="vertical-align: bottom; width: 13%; text-align: right"><font style="font-size: 10pt">1.325</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td>
<td style="vertical-align: bottom; width: 1%"> </td>
<td style="vertical-align: bottom; width: 1%"> </td>
<td style="vertical-align: bottom; width: 13%; text-align: right"><font style="font-size: 10pt">1.340</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td>
<td style="vertical-align: bottom; width: 1%"> </td>
<td style="vertical-align: bottom; width: 1%"> </td>
<td style="vertical-align: bottom; width: 13%; text-align: right"><font style="font-size: 10pt">1.325</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td>
<td style="vertical-align: bottom; width: 1%"> </td>
<td style="vertical-align: bottom; width: 1%"> </td>
<td style="vertical-align: bottom; width: 13%; text-align: right"><font style="font-size: 10pt">1.245</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td></tr>
<tr style="background-color: white">
<td style="vertical-align: top"><font style="font-size: 10pt">Average period/yearly GBP : US$ exchange rate</font></td>
<td style="vertical-align: bottom"> </td>
<td style="vertical-align: bottom"> </td>
<td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">1.279</font></td>
<td nowrap="nowrap" style="vertical-align: bottom"> </td>
<td style="vertical-align: bottom"> </td>
<td style="vertical-align: bottom"> </td>
<td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">1.382</font></td>
<td nowrap="nowrap" style="vertical-align: bottom"> </td>
<td style="vertical-align: bottom"> </td>
<td style="vertical-align: bottom"> </td>
<td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">1.283</font></td>
<td nowrap="nowrap" style="vertical-align: bottom"> </td>
<td style="vertical-align: bottom"> </td>
<td style="vertical-align: bottom"> </td>
<td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">1.370</font></td>
<td nowrap="nowrap" style="vertical-align: bottom"> </td>
<td style="vertical-align: bottom"> </td>
<td style="vertical-align: bottom"> </td>
<td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">1.315</font></td>
<td nowrap="nowrap" style="vertical-align: bottom"> </td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">Adjustments resulting from translating
the financial statements into the United States dollar are recorded as a separate component of accumulated other comprehensive
loss in stockholders' equity.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">(l) Recent accounting pronouncements</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">The Company continually assesses any new
accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the
Company's financial reporting, the Company undertakes a study to determine the consequences of the change to its consolidated financial
statements and assures that there are proper controls in place to ascertain that the Company's consolidated financial statements
properly reflect the change.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">In May 2014, the Financial Accounting
Standards Board ("FASB") issued Accounting Standards Updates ("ASU") No. 2014-09, Revenue from Contracts with
Customers. ASU 2014-09 has been modified multiple times since its initial release. This ASU outlines a single comprehensive model
for entities to use in accounting for revenue arising from contracts with customers and will replace most existing revenue recognition
guidance in U.S. GAAP when it becomes effective. ASU 2014-09, as amended, becomes effective for annual reporting periods beginning
after December 15, 2017. Early adoption is permitted. The Company is currently evaluating the impact that this standard will have
on its financial statements and related disclosures. The impact is expected to be insignificant until the Company begins to generate
revenue, except as to the possible impact related to the deferred revenue recorded in connection with the licensing agreement
described in Note 4 which the Company is currently evaluating. The standard permits the use of either the retrospective or cumulative
effect transition method. The Company has not yet selected a transition method.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">In March 2016, the FASB issued ASU No.
2016-02, Leases. The main difference between the provisions of ASU No. 2016-02 and previous U.S. GAAP is the recognition of right-of-use
assets and lease liabilities by lessees for those leases classified as operating leases under previous U.S. GAAP. ASU No. 2016-
02 retains a distinction between finance leases and operating leases, and the recognition, measurement, and presentation of expenses
and cash flows arising from a lease by a lessee have not significantly changed from previous U.S. GAAP. For leases with a term
of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize
right-of-use assets and lease liabilities. The accounting applied by a lessor is largely unchanged from that applied under previous
U.S. GAAP. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period
presented using a modified retrospective approach. This ASU is effective for public business entities in fiscal years, and interim
periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted as of the beginning of any interim
or annual reporting period. The Company has not yet determined the effect of the standard on its ongoing reporting.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">In August 2016, the FASB issued ASU No.
2016-15, Statement of Cash Flows - Classification of Certain Cash Receipts and Cash Payments. ASU No. 2016-15 is intended to reduce
diversity in how certain cash receipts and cash payments are presented in the statement of cash flows. The new guidance clarifies
the classification of cash activity related to debt prepayment or debt extinguishment costs, settlement of zero-coupon debt instruments,
contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, proceeds
from the settlement of corporate and bank-owned life insurance policies, distributions received from equity-method investments,
and beneficial interests in securitization transactions. The guidance also describes a predominance principle pursuant to which
cash flows with aspects of more than one class that cannot be separated should be classified based on the activity that is likely
to be the predominant source or use of cash flow. This ASU is effective for public entities for annual and interim periods beginning
after December 15, 2017. Early adoption is permitted as of the beginning of any interim or annual reporting period. The Company
is currently evaluating the impact this standard will have on its financial statements and related disclosures, but does not expect
it to have a material effect on the Company's consolidated financial statements and related disclosures.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">In November 2016, the FASB issued ASU No.
2016-18, Statement of Cash Flows - Restricted Cash. ASU 2016-18 requires entities to show the changes in the total of cash, cash
equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. When cash, cash equivalents, restricted
cash and restricted cash equivalents are presented in more than one line item on the balance sheet, a reconciliation of the totals
in the statement of cash flows to the related captions in the balance sheet is required. This ASU is effective for public entities
for annual and interim periods beginning after December 15, 2017. Early adoption is permitted as of the beginning of any interim
or annual reporting period. The Company is currently evaluating the impact this standard will have on its financial statements
and related disclosures.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">(m) Risks and uncertainties</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify">The Company is in the development stage
of one primary product that it expects to introduce to the UK market after completion of clinical trials and CE mark approval (European
Union approval of the product). The Company has entered into sales and marketing agreements for the product, but has not yet entered
into manufacturing agreements.  These matters raise uncertainties as regulatory acceptance of the Company’s primary
product development efforts and if acceptance is attained, the cost structure to produce the product.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 2.3pt 0; text-align: justify">(n) Subsequent events</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 2.3pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 2.3pt 0; text-align: justify">In October 2017, the Company’s
board of directors designated 200,000 shares of Series A Convertible Preferred Stock, as authorized by its articles of incorporation. 
The par value of the preferred stock is $0.001 per share. Each share of preferred stock is convertible into 1,000 shares of the
Company’s common stock, automatically upon the occurrence of certain triggering events, as set forth in the certificate of
designation, or voluntarily by the holder after February 1, 2019, if these triggering events have not occurred  Each holder
of issued and outstanding preferred stock is entitled to a number of votes equal to the number of shares of common stock into which
the preferred stock is convertible. Holders of preferred are entitled to vote on any and all matters presented to stockholders
of the Company, except as provided by law.  The preferred stock has preference to the common stock as to dividends or distributions
of assets upon liquidation or winding up of the Company.  Currently, no shares of preferred stock have been issued.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: justify"></p>
39581
-524323
-353401
-561360
614215
-62406
-639460
0
-967616
-498954
-54295
0
0
270210
39147
0
-221735
0
72401
-50241
17347
-86705
15031
11037
-800818
-816665
25245
55564
0
6842
205000000
205000000
205000000
205000000
506551
289870
238429
101768
864836
816665
447516
322482
-864836
-816665
-447516
-322482
64018
0
54485
0
-800818
-816665
-393031
-322482
-438754
-1206368
-233722
-182170
232138
203800
7683
9161
2020121
2830395
71844
51086
1350738
1867950
6995183
7401906
239821
212961
794626
852371
144646
87232
507376
687609
142604
77530
1272811
1183035
1272811
1183035
2067437
2035406
205000
205000
12919672
12919672
-7953451
-7152633
-243475
-605539
4927746
5366500
6995183
7401906
<p style="font: 10pt Times New Roman, Times, Serif; margin: 2.3pt 0"><b>NOTE 2 -- BASIS OF PRESENTATION</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 2.3pt 0; background-color: white"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 2.3pt 0"><b>(a)  Basis of presentation:</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 2.3pt 0; background-color: white"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 2.3pt 0; text-align: justify">The accompanying condensed consolidated
financial statements include the accounts of the Company and the Company’s subsidiaries, DDL, TCL, DDHL and RGL.  The
consolidated financial statements are prepared in accordance with the instructions to quarterly reports on Form 10-Q. In the opinion
of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position,
results of operations and changes in financial position at September 30, 2017 and for all periods presented have been made. Certain
information and footnote data necessary for fair presentation of financial position and results of operations in conformity with
accounting principles generally accepted in the United States of America have been condensed or omitted. It is therefore suggested
that these financial statements be read in conjunction with the summary of significant accounting policies and notes to financial
statements included in the Company’s Annual Report on Form 10-K for the Year Ended March 31, 2017.  The results of operations
for the period ended September 30, 2017 are not necessarily an indication of operating results for the full year.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 2.3pt 0; text-align: justify">(n) Subsequent events</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 2.3pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 2.3pt 0; text-align: justify">In October 2017, the Company’s
board of directors designated 200,000 shares of Series A Convertible Preferred Stock, as authorized by its articles of incorporation. 
The par value of the preferred stock is $0.001 per share. Each share of preferred stock is convertible into 1,000 shares of the
Company’s common stock, automatically upon the occurrence of certain triggering events, as set forth in the certificate of
designation, or voluntarily by the holder after February 1, 2019, if these triggering events have not occurred  Each holder
of issued and outstanding preferred stock is entitled to a number of votes equal to the number of shares of common stock into which
the preferred stock is convertible. Holders of preferred are entitled to vote on any and all matters presented to stockholders
of the Company, except as provided by law.  The preferred stock has preference to the common stock as to dividends or distributions
of assets upon liquidation or winding up of the Company.  Currently, no shares of preferred stock have been issued.</p>
Per share amounts are less than $0.01
These amounts are included primarily in research and development expenses charged to the Company by Pharma and NDM.